Cargando…

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria

BACKGROUND: HPV is a major cancer-causing factor in both sexes in the cervix, vulva, vagina, anus, penis, oropharynx as well as the causal factor in other diseases such as genital warts and recurrent respiratory papillomatis. In the context of the arrival of a nonavalent HPV vaccine (6/11/16/18/31/3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boiron, L., Joura, E., Largeron, N., Prager, B., Uhart, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833954/ https://www.ncbi.nlm.nih.gov/pubmed/27084683 http://dx.doi.org/10.1186/s12879-016-1483-5

Ejemplares similares

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2017)

Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
por: Gee, Julianne, et al.
Publicado: (2016)

Spotlight on the 9-valent HPV vaccine
por: Lopalco, Pier Luigi
Publicado: (2016)

HPV prevalence in vulvar cancer in Austria
por: Pils, Sophie, et al.
Publicado: (2017)

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
por: Moreira, E. D., et al.
Publicado: (2017)

Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions
por: Paz-Zulueta, María, et al.
Publicado: (2018)

Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study
por: Cody, Palmer, et al.
Publicado: (2021)

Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland
por: Kind, André B., et al.
Publicado: (2020)

Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines
por: Hartwig, Susanne, et al.
Publicado: (2015)

A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France
por: Bresse, Xavier, et al.
Publicado: (2013)

Costs and Cost-Effectiveness of 9-Valent Human Papillomavirus (HPV) Vaccination in Two East African Countries
por: Kiatpongsan, Sorapop, et al.
Publicado: (2014)

Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2023)

Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe
por: Marty, Rémi, et al.
Publicado: (2013)

Cost distribution of bluetongue surveillance and vaccination programmes in Austria and Switzerland (2007–2016)
por: Pinior, Beate, et al.
Publicado: (2018)

Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany
por: Préaud, Emmanuelle, et al.
Publicado: (2015)

Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine
por: Petry, Karl-Ulrich, et al.
Publicado: (2018)

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
por: Serrano, Beatriz, et al.
Publicado: (2012)

Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices
por: Petrosky, Emiko, et al.
Publicado: (2015)

Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
por: Mahumud, Rashidul Alam, et al.
Publicado: (2020)

Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain
por: Diez-Domingo, Javier, et al.
Publicado: (2010)

Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain
por: De La Fuente, Jesús, et al.
Publicado: (2019)

Correction: Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
por: Mahumud, Rashidul Alam, et al.
Publicado: (2023)

Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials
por: Petersen, Lone K., et al.
Publicado: (2017)

Tackling Vaccine Hesitancy and Increasing Vaccine Willingness Among Parents of Unvaccinated Children in Austria
por: Lenart, Christian, et al.
Publicado: (2023)

“Saving lives”: Adapting and adopting Human Papilloma Virus (HPV) vaccination in Austria
por: Paul, Katharina T.
Publicado: (2016)

Loss of chance associated with sub-optimal HPV vaccination coverage rate in France
por: Uhart, Mathieu, et al.
Publicado: (2017)

Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline
por: Min, Kyung-Jin, et al.
Publicado: (2019)

The Impact of 9-Valent HPV Vaccination on Couple Infertility Prevention: A Comprehensive Review
por: Ciavattini, Andrea, et al.
Publicado: (2021)

Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
por: Sundaram, Neisha, et al.
Publicado: (2017)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
por: Earnshaw, Stephanie R, et al.
Publicado: (2012)

Incorporating economies of scale in the cost estimation in economic evaluation of PCV and HPV vaccination programmes in the Philippines: a game changer?
por: Suwanthawornkul, Thanthima, et al.
Publicado: (2018)

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis
por: Kulasingam, Shalini L, et al.
Publicado: (2008)

Real-Life Safety Profile of the 9-Valent HPV Vaccine Based on Data from the Puglia Region of Southern Italy
por: Di Lorenzo, Antonio, et al.
Publicado: (2022)

Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China
por: Shen, Kunling, et al.
Publicado: (2018)

Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
por: Polistena, Barbara, et al.
Publicado: (2022)

1434. Cost-Effectiveness of Sequencial Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23 Valent Polysaccharide Vaccine (PPV23) in The Netherlands
por: Rozenbaum, Mark
Publicado: (2018)

Cost-effectiveness of Human Papilloma Virus (HPV) vaccination in Nigeria: a decision analysis using pragmatic parameter estimates for cost and programme coverage
por: Ekwunife, Obinna I., et al.
Publicado: (2017)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
por: Malene B, Mikkelsen, et al.
Publicado: (2023)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
por: Ngamprasertchai, Thundon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_21orti4kj5vpdimi12skdqs4d4